Navigation Links
RNL BIO Co. Ltd. stellt IND-Antrag, um klinische Phase-II-Studie des RNL-JointStem gegen Arthrose in den Vereinigten Staaten einzuleiten
Date:5/3/2013

rging, ist einer der größten Vorteile in der Tatsache zu sehen, dass das Produkt im Gegensatz zu vielen anderen invasiven Eingriffen, die derzeit zur Behandlung von AD eingesetzt werden, nur ein einziges Mal injiziert werden muss. „Die Behandlung dieser schmerzvollen chronischen Erkrankung sollte den Schmerz lindern und nicht verstärken", so Dr. Ra. „Wir hoffen nachzuweisen, dass RNL-JointStem wirksam zur Knorpelregeneration, Schmerzlinderung und Verbesserung der Gelenkfunktion von AD-Patienten beiträgt, und hoffen auf eine angemessen zeitnahe Marktzulassung."

Im Zuge der klinischen Studie wird RNL-JointStem mit bestehenden Verfahrensweisen auf Basis von Hyaluronsäure (HA) verglichen. Die Patientengruppe wird bei dieser klinischen Studie neben Patienten mit Arthrose-Befund auch weitere Patienten umfassen, deren Ärzte der Ansicht sind, dass sie die entsprechenden Teilnahmevoraussetzungen erfüllen. Der Zielmarkt für RNL-JointStem sind Patienten im Alter von unter 60 Jahren, für die derzeit keine wirksame Therapieoption besteht.

Informationen zu Arthrose

Die degenerative Arthritis ist die häufigste Form der Arthritis. Schätzungen zufolge leiden 26,9 Millionen Amerikaner ab einem Alter von 25 Jahren an degenerativer Arthritis bestimmter Gelenke. In älteren Bevölkerungsschichten ist der prozentuale Anteil des Krankheitsbefalls entsprechend höher. Zu den klinischen Manifestationen der Krankheit zählen Gelenkschmerz und Bewegungsbeeinträchtigung. Überdies ist das umliegende Gewebe häufig von lokalen Entzündungen befallen. Die Krankheitsursache der degenerativen Arthritis ist nicht vollständig erforscht. Verletzungen, Alter und die genetische Veranlagung gelten jedoch als Risikofaktoren.

Die degenerative Arthritis ist eine Krankheit, die progre
'/>"/>

SOURCE RNL BIO
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
2. Dr. Joachim Schorr (PhD) zum Chief Scientific Officer von Caris Life Sciences bestellt
3. Harvest Technologies Corporation erhält CE-Kennzeichnung für erweiterte klinische Indikation zur Behandlung nicht optionaler kritischer Extremitätenischämie
4. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
5. IDEV gibt Ergebnisse von Studie zur Revaskularisation mit Supera an echten Patienten (RESTORE) bekannt - Studie demonstriert positive klinische Ergebnisse bei schwerkranken Patienten mit langen Läsionen
6. Neue klinische Richtlinien für ältere Patienten mit Typ 2 Diabetes, um einen europaweiten Pflegenotstand zu verhindern
7. MR Solutions bringt vollständige Reihe heliumfreier präklinischer Magnetresonanztomographen auf den Markt
8. Neuartige Krebsimmuntherapie für den Beginn klinischer Studien bereit
9. Acutus Medical, Inc. erprobt erstmals seinen Echtzeit-3D-Bildgebungskatheter von CT/MRI-Qualität in einer klinischen Studie am Menschen
10. RNL BIO Co. Ltd. Files IND To Commence Phase II Clinical Trial Of RNL-JointStem For Osteoarthritis In The United States
11. RNL BIO Co. Ltd. lämnar in IND-ansökan om att påbörja klinisk fas II-prövning av RNL-JointStem för artros i USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  The Chemistry, ... Tobago Ministry of Health approved the introduction of ... increases the cure rate from Hepatitis C, and ... genotype 1 virus. Telaprevir is available in ... INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... , July 25, 2014  Solanbridge Group Inc ... acquired the majority interest in Buzznbrewz.com and the Letter ... replaced with a fully executed Purchase Agreement. ... stated "We are proud to have Mr. David ... decades of experience in the private sector and developed ...
(Date:7/25/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... Diagnostic Device An ophthalmic diagnostic device ... or deficiency in the human visual pathway. Ophthalmic devices ... presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... 14, 2012  Viztek, the digital imaging solution provider, announced ... Straight Arm. The DR solution, exclusively sold from Viztek ... cost and space-saving solution; the ViZion DR Straight Arm ... to Viztek,s front-end software. The complete ViZion ...
... Feb. 14, 2012  Organovo Holdings, Inc. (OTCQB: ONVO) ... merger on February 8, 2012, with Organovo, Inc. ... of three-dimensional bioprinting technology for research and medical ... private placement consisting of approximately 6.5 million units ...
Cached Medicine Technology:Organovo Announces $6.5 Million Private Placement to Advance 3D Bioprinting for Medical Applications 2Organovo Announces $6.5 Million Private Placement to Advance 3D Bioprinting for Medical Applications 3
(Date:7/26/2014)... According to the "Get Rid Tattoo ... a comprehensive guide that provides readers with safe and ... book also teaches them how to fade dark colored ... their own home for drastic results. , Vkool ... book includes step-by-step tutorials and product recommendations for treating ...
(Date:7/25/2014)... 26, 2014 PersonalInjurySolicitorsIreland, a legal ... to people who have suffered from a variety ... both their new company, and a website, ... new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , the law ... of the company is always on the client, ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 According ... Monitoring Market by Product (vibration monitoring, thermography, ultrasound ... signature analysis), Component, Application and Geography - Global ... the machine health monitoring market is expected to ... 2014 to 2020. , Browse 117 market data ...
(Date:7/25/2014)... 2014 As reported by the New Orleans ... Increasing (7/3), the state of Louisiana has recently seen ... even than cocaine. Officials believe the increase is due to ... “form” of marijuana. However, both doctors and police confirm that ... as to call it “poison,” doctors have acknowledged that the ...
(Date:7/25/2014)... Gerontological Society of America (GSA) the ... of aging has chosen Heather M. Young, ... Davis, as the 2014 recipient of the Doris ... honor, presented by GSA,s Health Sciences Section, is ... recognition of outstanding and sustained contribution to gerontological ...
Breaking Medicine News(10 mins):Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2
... BRUNSWICK, N.J., May 29 Johnson & Johnson,will ... & Diagnostics,businesses, as well as an update on ... 8:30 a.m. (Eastern Time) on Thursday,June 5, 2008, ... N.J., Donald Casey, Worldwide Chairman, Comprehensive Care ...
... program follows highly successful free antibiotic program ... date, GRAND RAPIDS, Mich., May 29 Supercenter ... in all 181 Meijer,pharmacies beginning June 1. The announcement ... for the Grand Rapids, Mich.-based retail chain., "As ...
... Three of the most terrifying words in,the English language ... and the fear factor rises even higher, since prostate cancer ... with early,detection is very curable., Give a gift of ... simple,blood test to screen for prostate cancer. If there is ...
... Physiology and Exercise Metabolism (Montana WPEM) will present a ... American College of Sports Medicine, showing that wildland ... supplement, Wellmune WGP, had far fewer 23 ... similar group of firefighters taking a placebo. , Montana ...
... Caraco Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) posted record ... March 31, 2008 (Fiscal 2008), of $191.8 million,and $350.4 ... for the corresponding periods of Fiscal 2007. Net income ... quarter and Fiscal 2008,respectively, as compared to net income ...
... ... through in silence, COSTA MESA, Calif., May 29 ... see healthy hair, they now see,an increasing proportion of scalp. Agonizing over ... sometimes even hair,extensions, which can actually further damage already stressed-out hair., ...
Cached Medicine News:Health News:Meijer Pharmacies to Offer Free Pre-Natal Vitamins 2Health News:Give the Man in Your Life the Gift of Health 2Health News:Montana Center for Work Physiology and Exercise Metabolism presents firefighter health study 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 7Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 8Health News:Hair Loss Is on the Rise, and Women Are Among the Hardest Hit 2
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
Medicine Products: